Indeed, the clinical benefit has been clearly demonstrated in a phase 2–3, double-blind, randomized trial that evaluated relatlimab and nivolumab as a fixed-dose combination as compared with nivolumab alone in patients with previously untreated metastatic or unresectable melanoma.7 Inhibition of both immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to progression-free survival (10.1 months (95% confidence interval [CI], 6.4–15.7)) with relatlimab–nivolumab as compared with 4.6 months (95% CI, 3.4–5.6) with nivolumab alone without showing new safety signals.7 This evidence concerns the gene LAG3 and melanoma.